Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced multiple presentations at AASLD’s The Liver Meeting®, November 7-11, 2025, in Washington, D.C., highlighting new clinical and real-world data for LIVMARLI (maralixibat) and volixibat.
Key items include an oral presentation on additional VANTAGE trial analyses showing volixibat improvements in fatigue and sleep for adults with primary biliary cholangitis (PBC) on November 10, multiple poster presentations on maralixibat real-world pruritus reduction, genetic testing insights from 856 panel tests, IL-31 and bile acid regulation data, and a Mirum-sponsored PFIC diagnosis and treatment fireside discussion on November 9.
Full abstracts are available on the AASLD website and detailed analyses will be posted on Mirum’s publications page after the conference.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported Q3 2025 total revenue of $133.0 million and updated 2025 revenue guidance to $500–$510 million. Q3 LIVMARLI net sales were $92.2 million (+56% vs Q3 2024); Bile Acid Medicines sales were $40.8 million (+31% vs Q3 2024). Total operating expenses were $130.4 million in Q3 2025, including $24.0 million of non-cash stock-based compensation and amortization. Cash, cash equivalents, and investments were $378.0 million as of September 30, 2025.
Pipeline catalysts: VISTAS (volixibat) enrollment complete with topline data expected in Q2 2026; VANTAGE and EXPAND expected to read out in H1 2027; Phase 2 MRM-3379 in Fragile X initiated. Company hosted a conference call on November 4, 2025.
Mirum Pharmaceuticals (Nasdaq: MIRM) said it will participate in two investor events in November 2025: a company presentation at the 2025 Stifel Healthcare Conference on Tuesday, November 11 at 8:40 a.m. ET and attendance at the J.P. Morgan U.S. Opportunities Forum 2025 on Wednesday, November 12.
Investors can find webcast links and additional information in the Investors and Media section of Mirum’s corporate website.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report third quarter 2025 financial results on November 4, 2025 and host a conference call the same day to discuss results and recent corporate progress.
The call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT on Tuesday, November 4, 2025. Dial-in numbers: US toll-free +1 833 470 1428; International +1 646 844 6383; Access Code: 299722. A live webcast will be available in the Events & Presentations section on Mirum’s website and a replay will be available for 30 days.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement equity awards on October 10, 2025 to eight new employees under its 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee granted non‑qualified stock options to purchase 45,800 shares with an exercise price of $72.71 (Mirum's closing price on October 10, 2025) and 22,850 restricted stock units (RSUs). Options vest over four years (25% at one year, then monthly over 36 months); RSUs vest over three years (33% each anniversary), each subject to continued service and the applicable award agreements.
Mirum Pharmaceuticals (NASDAQ:MIRM) announced the granting of inducement awards to four new employees under its 2020 Inducement Plan. The awards, approved by the Compensation Committee, include non-qualified stock options to purchase 10,820 shares at $74.89 per share and 5,390 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment.
Mirum Pharmaceuticals (Nasdaq: MIRM) has completed enrollment in its Phase 2b VISTAS study evaluating volixibat, an oral IBAT inhibitor, for treating cholestatic pruritus in primary sclerosing cholangitis (PSC) patients. The trial previously met its pre-specified efficacy and safety thresholds during a blinded interim analysis in 2024.
Topline results from the VISTAS study are expected in Q2 2026. Additionally, volixibat is being evaluated in the Phase 2b VANTAGE study for primary biliary cholangitis (PBC), with enrollment completion expected in 2026 and topline results in H1 2027.
Mirum Pharmaceuticals (NASDAQ:MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in five major investor conferences in September 2025.
The company will present at the Citi Biopharma Back-to-School Summit (Sept 3), Cantor Global Healthcare Conference (Sept 4, 3:20 PM ET), Morgan Stanley Global Healthcare Conference (Sept 8, 8:30 AM ET), Baird Global Healthcare Conference (Sept 9), and H.C. Wainwright Global Investment Conference (Sept 10, 10:00 AM ET). Webcasts will be available through Mirum's corporate website.
Mirum Pharmaceuticals (NASDAQ:MIRM) reported strong Q2 2025 financial results, with total revenue of $128 million, driven by robust commercial performance. The company raised its 2025 revenue guidance to $490-510 million.
LIVMARLI net product sales reached $88.2 million, showing 87% growth year-over-year, while Bile Acid Medicines generated $39.6 million in sales, up 30% from Q2 2024. The company launched LIVMARLI single oral tablet dose in the U.S. in June.
Mirum maintains a strong financial position with $321.7 million in cash and investments. The company's pipeline is advancing with three important late-stage clinical milestones expected in 2026, including the VISTAS study in PSC, VANTAGE study in PBC, and LIVMARLI EXPAND Phase 3 study.
Mirum Pharmaceuticals (NASDAQ:MIRM) has scheduled its second quarter 2025 financial results announcement and conference call for August 6, 2025 at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and provide updates on recent corporate developments.
Investors can join via phone using U.S. toll-free number +1 833 470 1428 or international number +1 404 975 4839 with access code 448461. A webcast option is available through Mirum's website Events & Presentations section, with replay access for 30 days following the call.